Widely used:Recently Viewed
Clear All
Today’s Range
52 Week Range
Liquidity
Market cap
$330 Mln
P/E Ratio
3.87
P/B Ratio
0.72
Industry P/E
--
Debt to Equity
--
ROE
0.01 %
ROCE
19.8 %
Div. Yield
16.5 %
Book Value
15.98
EPS
2.96
CFO
$-52.57 Mln
EBITDA
$484.77 Mln
Net Profit
$249.93 Mln
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|
|---|---|---|---|---|---|---|---|
|
TeklaLife Sciences Investors (HQL)
| -10.10 | -8.99 | -12.82 | -8.00 | -11.24 | -6.31 | -8.36 |
|
BSE Sensex
| 0.39 | 6.40 | 1.96 | 7.69 | 10.43 | 20.75 | 10.61 |
|
S&P Small-Cap 600#
| -5.82 | -5.34 | -13.73 | -6.30 | 5.30 | 2.98 | 5.53 |
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
2018
|
|
|---|---|---|---|---|---|---|---|
|
TeklaLife Sciences Investors (HQL)
| -2.51 | -5.28 | -26.11 | -2.63 | 13.31 | 15.35 | -22.92 |
|
S&P Small-Cap 600
| 7.01 | 13.89 | -17.42 | 25.27 | 9.57 | 20.86 | -9.70 |
|
BSE Sensex
| 8.10 | 18.74 | 4.44 | 21.99 | 15.75 | 14.38 | 5.87 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
3Y Avg -- 5Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | P/E Ratio | ROE |
|---|---|---|---|---|
| 5.85 | 1,719.50 | 9.06 | 1.87 | |
| 19.55 | 5,385.67 | 9.2 | 8.69 | |
| 11.81 | 1,955.10 | 2.1 | 43.05 | |
| 16.60 | 1,617.32 | 2.96 | 29.18 |
Abrdn Life Sciences Investors is a closed-ended equity mutual fund launched and managed by abrdn Inc. The fund invests in public equity markets across the globe. It seeks to invest in stocks of companies operating in the life sciences sector,... including the biotechnology, pharmaceutical, diagnostics, managed healthcare, medical equipment, hospitals, healthcare information technology and services, devices and supplies industries, and in agriculture and environmental management industries. The fund primarily invests in growth stocks of small cap companies. It employs fundamental analysis with a focus on factors such as market position for services or products, experience of business management, technological expertise, and the ability either to generate funds internally to finance growth or to secure outside sources of capital to create its portfolio. The fund benchmarks the performance of its portfolio against the NASDAQ Biotech Index and the S&P 500 Index. Abrdn Life Sciences Investors was formed on February 20, 1992 and is domiciled in the United States. Address: 1900 Market Street, Philadelphia, PA, United States, 19103 Read more
Principal Executive Officer, President and Trustee
Dr. Daniel R. Omstead M.S, Ph.D.
Principal Executive Officer, President and Trustee
Dr. Daniel R. Omstead M.S, Ph.D.
Headquarters
Philadelphia, PA
Website
Our rating system has guided millions of investors in the past 20 years.
The total asset value of TeklaLife Sciences Investors (HQL) stood at $ 461 Mln as on 30-Sep-24
The share price of TeklaLife Sciences Investors (HQL) is $11.80 (NYSE) as of 17-Apr-2025 15:30 EDT. TeklaLife Sciences Investors (HQL) has given a return of -11.24% in the last 3 years.
TeklaLife Sciences Investors (HQL) has a market capitalisation of $ 330 Mln as on 16-Apr-2025. As per Value Research classification, it is a Small Cap company.
The P/E ratio of TeklaLife Sciences Investors (HQL) is 3.87 times as on 16-Apr-2025.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the TeklaLife Sciences Investors (HQL) and enter the required number of quantities and click on buy to purchase the shares of TeklaLife Sciences Investors (HQL).
Abrdn Life Sciences Investors is a closed-ended equity mutual fund launched and managed by abrdn Inc. The fund invests in public equity markets across the globe. It seeks to invest in stocks of companies operating in the life sciences sector, including the biotechnology, pharmaceutical, diagnostics, managed healthcare, medical equipment, hospitals, healthcare information technology and services, devices and supplies industries, and in agriculture and environmental management industries. The fund primarily invests in growth stocks of small cap companies. It employs fundamental analysis with a focus on factors such as market position for services or products, experience of business management, technological expertise, and the ability either to generate funds internally to finance growth or to secure outside sources of capital to create its portfolio. The fund benchmarks the performance of its portfolio against the NASDAQ Biotech Index and the S&P 500 Index. Abrdn Life Sciences Investors was formed on February 20, 1992 and is domiciled in the United States. Address: 1900 Market Street, Philadelphia, PA, United States, 19103
The CEO & director of Dr. Daniel R. Omstead M.S, Ph.D.. is TeklaLife Sciences Investors (HQL), and CFO & Sr. VP is Dr. Daniel R. Omstead M.S, Ph.D..
There is no promoter pledging in TeklaLife Sciences Investors (HQL).
Some of the close peers are:
| Company | Market Cap($ Mln) |
|---|---|
|
549
|
|
|
191
|
|
|
172
|
|
|
162
|
| TeklaLife Sciences Investors (HQL) | Ratios |
|---|---|
|
Return on equity(%)
|
19.8
|
|
Operating margin(%)
|
--
|
|
Net Margin(%)
|
98.4
|
|
Dividend yield(%)
|
--
|
No, TTM profit after tax of TeklaLife Sciences Investors (HQL) was No Profit.
$0.14
(
